BETRF
BetterLife Pharma Inc.
Next earnings Jul 1, 2026
$0.13
▲ +30.50%$0.13▲ +113.93%
over 1Y
L $0.03H $0.13
Today+30.5%
1W+53.3%
1M+203.5%
3M+177.7%
YTD+350.0%
1Y+113.9%
Hold
Conviction
Horizon
Medium (3–12mo)
High return on equity (267.0%).
Return on equity 267.0% · latest
BetterLife Pharma Inc. shows limited reported revenue, and 267.0% ROE.
Supporting the case: high return on equity (267.0%); conservative balance sheet (liabilities/equity -9.46x).
Is BETRF a buy? The one-page verdict, explained →
The options angle
model · matches our verdictCovered call~60d expiry
- Long 100 shares @ ~0.13
- Short call 0 @ ~0.00 est
debit $13max +−$13max −$13
HOLD means own it, don't chase it — harvesting premium against the position matches the verdict.
Educational template, not a trade recommendation. Strikes and premiums are Black-Scholes model estimates from the last close and 30-day realized volatility — real chains, spreads and IV will differ. Options involve substantial risk.
Financials · annual, by fiscal year
| Line item | FY13 | FY15 | FY16 | FY17 | FY18 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | — | -$117K | -$10.3M | -$6.02M | -$1.05M |
| Net income | $341K | -$1.13M | -$10.3M | -$6.28M | -$121K |
| Diluted EPS | — | — | -$0.13 | -$0.08 | $0.00 |
| Net margin | — | — | — | — | — |
10-year statements — income, cash flow, balance sheet & CSV export →
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value$21.1M
EV / EBITDA—
EV / Sales—
EV / FCF—
P / FCF—
PEG (trailing)—
Earnings yield-0.6%
FCF yield—
Quality & risk
ROIC (est.)—
Free cash flow—
Total debt—
Net cash$64.5K
Piotroski F-Score1/6
Capital returns
Buyback yield—
Dividend yield (est.)—
Shareholder yield—
Shares Δ YoY+24.3%
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Disclosure timeline
SEC · 8-Ks + reportsRed flag in recent filings — late filing notice (2019-06-17). Worth a closer look.
Recent filings
all on EDGAR ↗6-KPeriod ending 2026-04-302026-06-26open ↗6-KPeriod ending 2026-06-252026-06-25open ↗20-FPeriod ending 2026-01-312026-06-01open ↗6-KPeriod ending 2026-04-132026-04-13open ↗6-KPeriod ending 2025-09-262025-09-29open ↗6-KPeriod ending 2025-07-282025-07-28open ↗6-KPeriod ending 2025-04-302025-06-27open ↗6-KPeriod ending 2025-06-232025-06-23open ↗20-FPeriod ending 2025-01-312025-06-02open ↗6-KPeriod ending 2025-05-292025-05-30open ↗6-KPeriod ending 2025-05-062025-05-07open ↗6-KPeriod ending 2025-04-072025-04-07open ↗
Frequently asked
- Is BetterLife Pharma Inc. (BETRF) a buy?
- BETRF currently carries a Hold rating with 3/5 conviction, derived from its latest SEC filings. High return on equity (267.0%).
- What is BetterLife Pharma Inc.'s quality score?
- BETRF scores 69.09090909090908/100 (grade B-) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.
Sources: SEC EDGAR (CIK 0001464165, latest 10-Q filed 2019-06-17) · EODHD · as of 6/18/2026, 12:43:08 PM.
About this recommendation — produced by TENK/calls (tenkcalls.com), Luxembourg · not investment advice
Rule-based analysis, generated automatically from SEC filing data.
Investment recommendation produced by TENK/calls (tenkcalls.com), Luxembourg. Completed Jun 18, 2026, 8:43 AM ET. Ratings & methodology: definitions · All recommendations to date: track record · Conflicts: disclosures. Not investment advice.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.